• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.

作者信息

Chunara Farheen, Lugo Chris, Osinski Kristen, Shah Mansi R, Shah Nishi, Kent Jessica, Mohyuddin Ghulam Rehman, Radhakrishnan Sabarinath Venniyil, Kaur Gurbakhash, Chakraborty Rajshekhar, Banerjee Rahul, Rasche Leo, Schinke Carolina, D'Souza Anita, Szabo Aniko, Mohan Meera

机构信息

Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.

TriNetX LLC, Cambridge, MA, USA.

出版信息

Blood Cancer J. 2025 Apr 8;15(1):61. doi: 10.1038/s41408-025-01254-4.

DOI:10.1038/s41408-025-01254-4
PMID:40199861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11979001/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e5b/11979001/6bcaed4c99d3/41408_2025_1254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e5b/11979001/789ee8f4a993/41408_2025_1254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e5b/11979001/6bcaed4c99d3/41408_2025_1254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e5b/11979001/789ee8f4a993/41408_2025_1254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e5b/11979001/6bcaed4c99d3/41408_2025_1254_Fig2_HTML.jpg

相似文献

1
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.多发性骨髓瘤（MM）中替西帕单抗和他喹莫单抗的真实世界治疗模式：609例患者的经验
Blood Cancer J. 2025 Apr 8;15(1):61. doi: 10.1038/s41408-025-01254-4.
2
Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers.真实世界中 talquetamab 治疗复发/难治性多发性骨髓瘤的临床管理经验：美国医疗保健提供者的定性研究。
Curr Med Res Opin. 2024 Oct;40(10):1705-1711. doi: 10.1080/03007995.2024.2387183. Epub 2024 Aug 23.
3
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.塔奎他单抗联合替西他单抗治疗复发或难治性多发性骨髓瘤
N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536.
4
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.T 细胞特征影响多发性骨髓瘤中 T 细胞重定向双特异性抗体的反应和耐药性。
Clin Cancer Res. 2024 Jul 15;30(14):3006-3022. doi: 10.1158/1078-0432.CCR-23-3333.
5
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study.关于在现实世界中使用替西帕单抗的肿瘤学实践的小组访谈：TecPIONEER研究
Curr Med Res Opin. 2024 May 16:1-6. doi: 10.1080/03007995.2024.2352856.
6
Talquetamab in multiple myeloma.塔奎单抗治疗多发性骨髓瘤。
Haematologica. 2024 Mar 1;109(3):718-724. doi: 10.3324/haematol.2023.283931.
7
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.在 LocoMMotion 和 MoMMent 研究中，比较 Talquetamab 与现有疗法在三药暴露复发/难治性多发性骨髓瘤患者中的疗效。
Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24.
8
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.替西妥单抗和他喹妥单抗对复发/难治性多发性骨髓瘤患者可溶性BCMA水平的影响。
Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625.
9
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.在 Prospective LocoMMotion 研究中，三药暴露复发和/或难治性多发性骨髓瘤患者的真实世界临床实践中，替西罗莫司与现有治疗方案的疗效比较。
Adv Ther. 2023 May;40(5):2412-2425. doi: 10.1007/s12325-023-02480-7. Epub 2023 Mar 24.
10
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.在三药暴露复发/难治性多发性骨髓瘤中，特里斯他单抗与现实世界中医生治疗选择的比较疗效：LocoMMotion 和 MoMMent 研究。
Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.

引用本文的文献

1
Bispecific antibodies: unleashing a new era in oncology treatment.双特异性抗体：开启肿瘤治疗的新时代。
Mol Cancer. 2025 Aug 4;24(1):212. doi: 10.1186/s12943-025-02390-y.

本文引用的文献

1
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.复发/难治性骨髓瘤患者接受有限疗程双特异性抗体治疗后的持续缓解
Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.
2
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.特卡司他单抗治疗复发/难治性多发性骨髓瘤：多机构真实世界研究。
Blood Cancer J. 2024 Mar 5;14(1):35. doi: 10.1038/s41408-024-01003-z.
3
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
特卡昔单抗可损害经大量预处理的骨髓瘤患者的体液免疫：免疫球蛋白补充的重要性。
Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658.
4
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.复发/难治性多发性骨髓瘤患者中，针对 BCMA 和 GPRC5D 的双特异性抗体（bsAb）治疗的感染谱变化。
Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590.
5
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.塔奎单抗，一种用于多发性骨髓瘤的靶向 GPRC5D 的 T 细胞双特异性抗体。
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
6
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.